SEC Form 3 · accession 0000899243-18-001955
Solid Biosciences Inc. · SLDB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jan 25, 2018
Accepted (ET)
Jan 25, 2018 · 6:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001707502
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | holding | — | — | — | 3,031,601 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1JPMC Strategic Investments II Corporation is the record holder of 3,031,601 shares of Common Stock. JPMC Strategic Investments II Corporation is a wholly-owned subsidiary of JPMorgan Chase & Co., a publicly traded entity listed on the New York Stock Exchange.
- F2Upon the consummation of the initial public offering of Solid Biosciences Inc., the reporting persons will own less than 10% of the outstanding shares of Common Stock of Solid Biosciences.